School of Medicine, American University of Integrative Sciences (AUIS), Bridgetown, Barbados.
Expert Rev Clin Pharmacol. 2021 May;14(5):601-621. doi: 10.1080/17512433.2021.1902303. Epub 2021 May 3.
The COVID-19 pandemic has created a public health crisis, infected millions of people, and caused a significant number of deaths. SARS-CoV-2 transmits from person to person through several routes, mainly via respiratory droplets, which makes it difficult to contain its spread into the community. Here, we provide an overview of the epidemiology, pathogenesis, clinical presentation, diagnosis, and treatment of COVID-19.
Direct person-to-person respiratory transmission has rapidly amplified the spread of coronavirus. In the absence of any clinically proven treatment options, the current clinical management of COVID-19 includes symptom management, infection prevention and control measures, optimized supportive care, and intensive care support in severe or critical illness. Developing an effective vaccine is now a leading research priority. Some vaccines have already been approved by the regulatory authorities for the prevention of COVID-19.
General prevention and protection measures regarding the containment and management of the second or third waves are necessary to minimize the risk of infection. Until now, four vaccines reported variable efficacies of between 62-95%, and two of them (Pfizer/BioNTech and Moderna) received FDA emergency use authorization. Equitable access and effective distribution of these vaccines in all countries will save millions of lives.
COVID-19 大流行造成了公共卫生危机,感染了数百万人,并导致大量死亡。SARS-CoV-2 通过几种途径在人与人之间传播,主要通过呼吸道飞沫,这使得很难控制其在社区中的传播。在这里,我们提供了 COVID-19 的流行病学、发病机制、临床特征、诊断和治疗的概述。
直接的人与人之间的呼吸道传播迅速扩大了冠状病毒的传播。在没有任何临床证实的治疗方法的情况下,目前 COVID-19 的临床管理包括症状管理、感染预防和控制措施、优化的支持性护理以及严重或危急疾病的重症监护支持。开发有效的疫苗现在是首要的研究重点。一些疫苗已经获得监管机构批准,可用于预防 COVID-19。
为了最大限度地降低感染风险,需要针对遏制和管理第二波或第三波疫情采取一般预防和保护措施。到目前为止,报告的四种疫苗的有效性在 62%-95%之间,其中两种(辉瑞/生物技术和 Moderna)已获得 FDA 紧急使用授权。在所有国家公平地获得和有效分配这些疫苗将拯救数百万人的生命。